Tian Zhang, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Grants

Publications

Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.

Full Text

Labriola, Matthew, Jason Zhu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:e14259–e14259. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14259.

Full Text

Pabla, Sarabjot, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, Edwin Yau, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.” In Journal of Clinical Oncology, 37:61–61. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.61.

Full Text

Glenn, Sean T., Sarabjot Pabla, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.” In Journal of Clinical Oncology, 37:62–62. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.62.

Full Text

Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:63–63. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.63.

Full Text

Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:607–607. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.607.

Full Text

Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.

Full Text

Zhang, Tian, Janet S. Staats, Cliburn Chan, Ajjai Shivaram Alva, Peter H. O’Donnell, Michael Roger Harrison, Kristen A. Batich, Veerendra Munugalavadla, Daniel J. George, and Kent J. Weinhold. “Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).” In Journal of Clinical Oncology, 37:357–357. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.357.

Full Text

Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:589–589. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.589.

Full Text

Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:400–400. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.400.

Full Text

Pages